Roche lung cancer therapy beats rivals from Amgen, BMS in late-stage trial
Seeking Alpha ·
Roche ( RHHBY ) unit Genentech announced on Thursday its KRAS G12C inhibitor divarasib outperformed FDA-approved KRAS G12C inhibitors from Amgen ( AMGN ) and Bristol Myers Squibb ( BMY ) in a late-stage trial for patients with non-small cell lung cancer.
DYAX Investor Sentiment
Bullish (Long) 74% · Bearish (Short) 26%
408 participants
Related News
- Franklin Senior Loan ETF declares monthly distribution of $0.​12654
- Franklin International Aggregate Bond ETF declares monthly distribution of $0.​03767
- Agnico Eagle suspends operations at Barnat pit after rock movement
- Hassett seems to confirm Trump administration is talking to AI firms about a possible stake
- Franklin High Yield Corporate ETF declares monthly distribution of $0.​12841
- CME's Q2 daily volume hits its second-highest reading